{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:09:01Z","timestamp":1791223741426,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1043,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.bbmt.2011.11.028","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T17:17:50Z","timestamp":1323364670000},"page":"951-957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Tandem Autologous\u2013Allogeneic Nonmyeloablative Sibling Transplantation in Relapsed Follicular Lymphoma Leads to Impressive Progression-Free Survival with Minimal Toxicity"],"prefix":"10.1016","volume":"18","author":[{"given":"Sandra","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvy","family":"Lachance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis Claude","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Sauvageau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Busque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.11.028_bib1","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib2","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1023\/A:1008399623564","article-title":"High-dose therapy with autologous stem cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol","volume":"11","author":"Brice","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib3","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.028_bib4","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib5","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V83.12.3780.3780","article-title":"Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late\u00a0complication of curative cancer therapy","volume":"83","author":"Miller","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.028_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002770050503","article-title":"High-dose therapy and stem cell transplantation in follicular lymphoma","volume":"78","author":"Friedberg","year":"1999","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib7","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2011.11.028_bib8","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib9","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.1994.12.12.2535","article-title":"Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma","volume":"12","author":"Stone","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.bbmt.2008.04.007","article-title":"Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma","volume":"14","author":"Kuruvilla","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib11","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.028_bib12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib13","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.028_bib15","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","article-title":"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation","volume":"343","author":"Childs","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2011.11.028_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.bmt.1703215","article-title":"A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome","volume":"28","author":"Kroger","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib17","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.2001.19.14.3340","article-title":"Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome","volume":"19","author":"Michallet","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib18","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.028_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2003-05-1406","article-title":"BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients","volume":"103","author":"Faulkner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.028_bib20","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.028_bib21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3324\/haematol.10924","article-title":"Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)","volume":"92","author":"Vigouroux","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2011.11.028_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib23","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1182\/blood-2008-01-136242","article-title":"Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab","volume":"111","author":"Khouri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.028_bib24","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","article-title":"T-cell\u2013depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma","volume":"28","author":"Thomson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib25","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib26","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin\u2019s lymphoma","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib27","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2013an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/oxfordjournals.annonc.a059252","article-title":"A phase II trial of mesna\/ifosfamide, mitoxantrone and etoposide for refractory lymphomas","volume":"6","author":"Rodriguez","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib29","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin\u2019s lymphoma","volume":"17","author":"Moskowitz","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib30","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"NCI Sponsored International Working Group. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.bmt.1702531","article-title":"A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin\u2019s disease or non-Hodgkin\u2019s lymphoma","volume":"26","author":"Stiff","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib32","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/annonc\/9.suppl_1.S15","article-title":"Conditioning regimens before transplantation in patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"9","author":"Mounier","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00277-007-0360-0","article-title":"BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: comparative analysis of efficacy and toxicity","volume":"87","author":"Jo","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbmt.2009.04.004","article-title":"Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality","volume":"15","author":"Sabry","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.exphem.2005.09.013","article-title":"Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation","volume":"34","author":"Dhedin","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2011.11.028_bib36","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease, I: Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib37","first-page":"825","article-title":"1994 Consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib38","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced-intensity conditioning HLA-identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials","volume":"95","author":"Pinana","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2011.11.028_bib39","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2004-01-0200","article-title":"Duration of immunosuppressive treatment for chronic graft-versus-host disease","volume":"104","author":"Stewart","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.11.028_bib40","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.bbmt.2009.02.009","article-title":"Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation","volume":"15","author":"Nakamae","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib41","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.bmt.1704164","article-title":"Cytomegalovirus infections in allogeneic stem cell recipients after reduced-intensity or myeloablative conditioning assessed by quantitative PCR and pp65-antigenemia","volume":"32","author":"Schetelig","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1399-3062.2007.00247.x","article-title":"Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders","volume":"10","author":"Kim","year":"2008","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.bbmt.2011.11.028_bib43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/sj.bmt.1702190","article-title":"Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir","volume":"25","author":"Steer","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.11.028_bib44","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.bbmt.2010.10.025","article-title":"High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation","volume":"17","author":"Su","year":"2011","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111005441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111005441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:41:24Z","timestamp":1761057684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111005441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1083879111005441"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.11.028","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tandem Autologous\u2013Allogeneic Nonmyeloablative Sibling Transplantation in Relapsed Follicular Lymphoma Leads to Impressive Progression-Free Survival with Minimal Toxicity","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}